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Findings 
Triangular marker placed in the upper outer quadrant  
of the right breast over the area of  palpable mass. 
• Palpable mass correlated with a highly suspicious 
focal asymmetry with associated architectural 
distortion.
• Ultrasound indicated a highly suspicious mass  
found 4 cm from the nipple. Mass had irregular 
borders and was hyperechoic on ultrasound. No 
suspicious axillary lymph nodes located. 
• The patient was categorized utilizing  Breast Imaging 
Reporting and Data System(BI-RADS) which  
assesses risk of malignancy. Categorized as BI-RADS 
5 which is highly suggestive of malignancy.
• Specimen of the right breast mass was obtained by 
ultrasound guided biopsy. 
• Surgical pathology report indicated invasive
mammary carcinoma Nottingham Grade Three.
The Nottingham Grade is a scoring system used for 
assessment of breast cancers grade one being least 
aggressive and grade three being most aggressive. 
There was no lymphovascular invasion seen (Thomas 
P. Saxton Medical Pavilion, 2021).
Additional Research Results
According to the World Health Organization (WHO) 
approximately 146,000 new breast cancer cases are 
reported in women younger than 40 worldwide each 
year (Fabiano, Mando, Rizzo, Ponce, Colo, Loza, Loza, 
Amat, Mysler, Costanzo, Nervo, Nadal…,2020).
Tumors are more likely to be clinically detectable in 
young women when compared to women over the age 
of 40. According to Langman et al., 91.8% (101) of the 
patients in their research study presented with a 
palpable mass (2021).
Diagnosis Variations Between Older & 
Younger Women
American College of Radiology (ACR) Appropriateness
Criteria for palpable breast lumps states that 
mammography or digital breast tomosynthesis can aid 
in the detection of additional lesions in young patients 
no matter their age who have suspicious clinical or 
imaging findings (Langman et al., 2021).
Differences in tumor size, histologic subtypes, 
tumor grade, and lymphovascular invasion were seen 
between young patients and in patients older than 40.
Women under the age of 40 are often diagnosed 
with breast cancer at a later stage of the disease and 
have a poorer prognosis due to lack of widely used 
screening techniques.
A higher proportion of family history of 
breast cancer was found in young women in 
comparison to women greater than 40 years old 
(Fabiano et al., 2020).
Breast cancer in young women is unique and differs 
from breast cancer in women older than 40 in imaging 
findings, tumor biology, and clinical course.
Breast cancer in the patients younger than 40 years 
old often presents as multifocal or multicentric disease 
with malignant microcalcifications only visible on 
mammography (Langman et al., 2021).
To a limited extent it is believed that young women 
with breast cancer have inferior clinical outcomes. The 
main reason for mortality disparities is the biologic 
variability in young patients as compared to older 
patients. Age alone is not believed to be a contributing 
factor to the biologic complexity of a patient’s breast 
cancer (Fabiano et al., 2020).
Cancer Types
About 80% of breast cancers are ER-
positive which means that the cancer cells respond to 
the hormone estrogen. Between 10-20% of breast 
cancers are triple negative. This means that the cancer 
cells do not have estrogen or progesterone receptors 
and does not overexpress the HER2 protein (Shaw, 
n.d.) Research found that breast cancer recurred in 
16.4% (18) of patients. The average time to recurrence 
in the study’s population was 9.01 years from time of 
diagnosis. Patients who were ER positive had a 
statistically higher risk of recurrence whereas patients 
who were triple-negative nearly had recurrence-
free survival. Overall survival of the research study was 
favorable with only 1.8% (2) known deaths within 5-7 
years after diagnosis (Langman et al., 2021).
Types of Therapy
Research indicates , breast conserving therapy 
was performed in 62.89% of younger patients which is 
a substantially lower rate than older patients. In 
patients 40 years old and younger, adjuvant 
chemotherapy was used as treatment for 59.04% of 
patients whereas 36.66% of patients older than 40 
underwent this treatment (Fabiano et al., 2020).
Neoadjuvant chemotherapy was used as 
treatment for 17.59% of younger patients and 8.37% 
of older patients (Fabiano et al., 2020). Mastectomy 
was part of treatment for most patients. Many 
patients in Langman et al.’s (2021) study underwent 
neoadjuvant chemotherapy, and radiation therapy was 
also a common treatment for young patients (2021).
C
Conclusion
Additional research on invasive breast cancers in the 
young population is necessary. In order to improve 
outcomes, special consideration for young patients 
with invasive breast cancer are needed relative to 
both diagnosis and treatment . When compared to 
women over the age of 40, imaging findings, tumor 
biology and clinical course are unique in young women 
(Langman et al., 2021). Breast cancer in young women 
is often associated with more aggressive forms of 
cancers as well as a worse prognosis. A limitation of 
the case study is that the patient decided to seek a 
second opinion from an outside facility and treatment 
and outcomes are unknown. Limitations of both 
research studies utilized in this project are small 
sample sizes, which further supports the need for 
additional research.
Introduction
Breast cancer is the leading cause of cancer-related 
death in young women ages 15-3 in the 
United States (Langman, Kuzmiak, Brader, Thomas, 
Alexander, Lee, & Jordan 2021). Currently, there is not 
a widely used breast cancer screening for young 
women absent of known risk factors; resulting in 
younger women being diagnosed at a more advanced
stages of the disease process. Many young women 
often present with findings such as palpable lumps, 
pain, nipple discharge, and changes in the skin of the 
breast. Imaging of young women aims to keep 
radiation dose as low as possible while targeting the 
symptomatic area (Langman, et al., 2021). Ultrasound 
is the typical initial imaging examination in patients 
younger than 30 followed by mammography if the 
ultrasound findings are suspicious.
Invasive breast cancer is often the diagnosis for 
these young women. Invasive breast cancers are 
cancers that have invaded or infiltrated into the 
surrounding healthy tissue (Breastcancer.org, n.d.). 
Invasive mammary carcinoma is defined as a tumor 
that has features of both ductal carcinoma and lobular 
carcinoma (Johns Hopkins Medicine, n.d.). It is 
considered a mixed tumor and typically begins as 
ductal carcinoma that has spread to the surrounding 
lobules (Breastcancer.org, n.d)
Case Study
Subject:34-year-old patient presenting with a right 
palpable breast lump measuring 1.9 cm on 
mammographic images.
Imaging: Diagnostic mammogram with spot 
compression of the area, ultrasound followed by 
ultrasound guided breast biopsy.
Bilateral diagnostic tomosynthesis and two-
dimensional synthesized images were performed.
Diagnosis: Invasive Mammary Carcinoma.
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(Thomas P. Saxton Medical Pavilion, 2021). 
Comparison of an abnormal 
mammogram indicating invasive 
mammary carcinoma (left) and a 
mammogram with benign 
findings (right) (Thomas P. Saxton 
Medical Pavilion, 2021).
